Radical prostatectomy is surgery to remove all of the prostate gland and some of the tissue around it, to treat prostate cancer.
Approximately 14 percent of men will be diagnosed with prostate cancer at some point in their lifetimes, according to the National Institutes of Health. Radiation therapy traditionally has been a primary treatment for the cancer, but one-fourth of men have a recurrence of prostate cancer within five years after the therapy.
A new study provides a major link between low levels of vitamin D and aggressive prostate cancer. Northwestern Medicine research showed deficient vitamin D blood levels in men can predict aggressive prostate cancer identified at the time of surgery.
Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85 percent accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery.
For most men with low-risk prostate cancer, the recommended strategy is active surveillance with regular testing to check for cancer growth rather than immediate treatment, according to guidelines from the American Society of Clinical Oncology.
Advances in Radiation Oncology, ASTRO's new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy.
The System Partner of Rutgers Cancer Institute of New Jersey, Meridian Health is joining forces with Rutgers Cancer Institute in offering access to a research study aimed at prostate cancer patients who are transitioning to survivorship.
Researchers at the University of Copenhagen have identified a new prognostic biomarker: the neuropeptide pro-NPY, which may help determine the risk of dying from prostate cancer. This particular type of protein is very specific to prostate cancer cells and could help identify whether newly diagnosed patients require radical prostatectomy surgery or if it is safe to delay surgery.
Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today.
A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.
Patients who have undergone radical prostatectomy often have largely unrealistic expectations with regard to their postoperative sexual function, new research shows.
Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.
Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.
GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant predictor of metastasis in patients treated with postoperative salvage radiation therapy.
A "perverse disincentive" for hospitals that have invested in expensive technology for robotic surgery may be jeopardizing prostate cancer patients who seek out the procedure, concluded a new study led by Henry Ford Hospital researchers.
Quitting smoking can lead to a significant improvement in outcomes after major urologic surgery. These new data and their impact on urologic surgery will be highlighted by study authors during a special press conference at the 110th Annual Scientific Meeting of the American Urological Association.
A recent study reported in The Journal of Nuclear Medicine compared use of the novel Ga-68-PSMA-ligand PET/CT with other imaging methods and found that it had substantially higher detection rates of prostate-specific membrane antigen (PSMA) in patients with biochemical recurrence after radical prostatectomy.
Doctors strive to make treatment decisions together with their patients - but is the decision really shared? According to adjunct professor Kari Tikkinen, shared decision-making isn't easy, and clinicians need help. The international research group led by Tikkinen has studied the decision aids for treatment choice of localised prostate cancer
UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.
Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.